Nothing Special   »   [go: up one dir, main page]

PT3660033T - Análogos de compstatina de longa ação e composições e métodos relacionados - Google Patents

Análogos de compstatina de longa ação e composições e métodos relacionados

Info

Publication number
PT3660033T
PT3660033T PT192054260T PT19205426T PT3660033T PT 3660033 T PT3660033 T PT 3660033T PT 192054260 T PT192054260 T PT 192054260T PT 19205426 T PT19205426 T PT 19205426T PT 3660033 T PT3660033 T PT 3660033T
Authority
PT
Portugal
Prior art keywords
methods
long
related compositions
compstatin analogs
acting compstatin
Prior art date
Application number
PT192054260T
Other languages
English (en)
Original Assignee
Apellis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apellis Pharmaceuticals Inc filed Critical Apellis Pharmaceuticals Inc
Publication of PT3660033T publication Critical patent/PT3660033T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Detergent Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT192054260T 2012-11-15 2013-11-15 Análogos de compstatina de longa ação e composições e métodos relacionados PT3660033T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261727094P 2012-11-15 2012-11-15

Publications (1)

Publication Number Publication Date
PT3660033T true PT3660033T (pt) 2021-07-06

Family

ID=50731833

Family Applications (2)

Application Number Title Priority Date Filing Date
PT192054260T PT3660033T (pt) 2012-11-15 2013-11-15 Análogos de compstatina de longa ação e composições e métodos relacionados
PT138549902T PT2920201T (pt) 2012-11-15 2013-11-15 Análogos de compstatina de longa ação e composições e métodos relacionados

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT138549902T PT2920201T (pt) 2012-11-15 2013-11-15 Análogos de compstatina de longa ação e composições e métodos relacionados

Country Status (24)

Country Link
US (4) US10035822B2 (pt)
EP (3) EP3660033B9 (pt)
JP (5) JP2016505527A (pt)
CN (2) CN110882376B (pt)
AU (4) AU2013344462B2 (pt)
BR (1) BR112015011244B1 (pt)
CA (1) CA2891673A1 (pt)
CY (1) CY1124474T1 (pt)
DK (2) DK2920201T3 (pt)
ES (2) ES2780674T3 (pt)
FR (1) FR22C1025I2 (pt)
HK (2) HK1215445A1 (pt)
HR (1) HRP20211342T2 (pt)
HU (2) HUE055564T2 (pt)
IL (2) IL238852A0 (pt)
LT (2) LT3660033T (pt)
MX (2) MX366404B (pt)
NL (1) NL301178I2 (pt)
NO (1) NO2022017I1 (pt)
PL (2) PL2920201T3 (pt)
PT (2) PT3660033T (pt)
RS (1) RS62243B9 (pt)
SI (1) SI3660033T1 (pt)
WO (1) WO2014078731A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
BR112013028816B1 (pt) 2011-05-11 2020-12-15 Apellis Pharmaceuticals, Inc Análogos de compstatina, composição que os compreende e uso dos mesmos
HUE055564T2 (hu) 2012-11-15 2021-11-29 Apellis Pharmaceuticals Inc Hosszan ható compstatin-analógok és kapcsolódó készítmények, valamint módszerek
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
JP6968787B2 (ja) * 2015-10-07 2021-11-17 アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals, Inc. 投与レジメン
US11338013B2 (en) * 2016-10-17 2022-05-24 Apellis Pharmaceuticals, Inc. Combination therapy for C3 inhibition
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
EP3589628A4 (en) 2017-03-01 2021-03-31 Achillion Pharmaceuticals, Inc. ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISEASES
WO2018187813A1 (en) 2017-04-07 2018-10-11 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
CN111163767A (zh) 2017-08-02 2020-05-15 艾其林医药公司 治疗阵发性睡眠性血红蛋白尿症的治疗方案
CN109701030A (zh) * 2017-10-26 2019-05-03 湖南华腾制药有限公司 聚乙二醇化小分子药物的制备方法
KR20200123091A (ko) * 2017-12-15 2020-10-28 아펠리스 파마슈티컬스 인코포레이티드 투여 요법 및 관련 조성물 및 방법
PT3645550T (pt) 2018-04-06 2022-02-01 Univ Pennsylvania Análogos de compstatina com solubilidade aumentada e melhores propriedades farmacocinéticas
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
WO2020051538A1 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド 医学的障害の治療のための大環状化合物
AU2019346464A1 (en) 2018-09-25 2021-04-08 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor D inhibitors
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
US11510939B1 (en) 2019-04-19 2022-11-29 Apellis Pharmaceuticals, Inc. RNAs for complement inhibition
CN110244053B (zh) * 2019-05-09 2022-03-11 北京大学第三医院（北京大学第三临床医学院） 用于诊断狼疮肾炎并肺动脉高压疾病的分子标志物及其用途
EP3996744A4 (en) * 2019-07-05 2023-07-12 Apellis Pharmaceuticals, Inc. VIRAL VECTOR THERAPY
WO2021011927A1 (en) * 2019-07-18 2021-01-21 Apellis Pharmaceuticals, Inc. Complement inhibitor dosing regimens
CN111235264B (zh) * 2020-02-20 2023-05-16 圣湘生物科技股份有限公司 检测人tpmt基因和nudt15基因多态性的组合物、试剂盒及方法
CN111265651A (zh) * 2020-02-29 2020-06-12 华中科技大学同济医学院附属同济医院 补体c3抑制剂cp40-kk在制备防治肺动脉高压病药物中的应用
US20230158063A1 (en) * 2020-04-06 2023-05-25 The Trustees Of Indiana University Airway epithelial alkaline therapy to treat viral respiratory infection
CN118812653A (zh) * 2023-04-18 2024-10-22 成都奥达生物科技有限公司 一种长效坎普他汀化合物

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2295746A1 (fr) 1974-12-23 1976-07-23 Francaise Coop Pharma Nouveaux derives du tryptophane a activite nerveuse centrale renforcee
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IT1179866B (it) 1984-12-12 1987-09-16 Rotta Research Lab Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono
US4576750A (en) 1985-04-22 1986-03-18 Merck & Co., Inc. Tryptophan derivative
US5157110A (en) 1988-08-20 1992-10-20 The Government Of The United States Of America Synthetic, anti-complement protein
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
IL95942A0 (en) 1989-10-13 1991-07-18 Syntex Inc Collagen-containing ophthalmic formulation
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
EP0512733A2 (en) 1991-05-03 1992-11-11 Washington University Modified complement system regulator
US5492135A (en) 1992-09-09 1996-02-20 Devore; Dale P. Collagen modulators for use in photoablation excimer laser keratectomy
US5482135A (en) 1993-06-29 1996-01-09 Deere & Company Combined hydraulic reservoir and vehicle axle
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5770589A (en) 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5776970A (en) 1994-04-28 1998-07-07 Yeda Research And Development Co. Ltd. Tryptophan derivatives as protein tyrosine kinase blockers and their use in the treatment of neoplastic diseases
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
JPH08280800A (ja) 1995-04-12 1996-10-29 Nissho Corp ２液注射用プレフィルドシリンジ
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6129761A (en) 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US6319897B1 (en) 1996-03-13 2001-11-20 John D. Lambris Peptides which inhibit complement activation
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
WO1997047321A1 (en) 1996-06-14 1997-12-18 The Johns Hopkins University School Of Medicine Use of chimeric vaccinia virus complement control proteins to inhibit complement
JPH1087700A (ja) 1996-06-17 1998-04-07 Smithkline Beecham Corp Ｃ３ａ受容体およびＣ３ａを用いる治療およびスクリーニング方法
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
WO1998047002A2 (en) 1997-04-11 1998-10-22 Advanced Medicine, Inc. Polyvalent presenter combinatorial libraries and their uses
CN1269013A (zh) 1997-04-11 2000-10-04 高级药品有限公司 呈递多个活性部分的分子
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
US6169057B1 (en) 1997-09-04 2001-01-02 The Regents Of The University Of California Use of tryptophan and analogs as plant growth regulators
AU4648197A (en) 1997-09-17 1999-04-05 Burnham Institute, The Peptides and peptidomimetics for inhibiting complement activation
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
JPH11197234A (ja) 1998-01-09 1999-07-27 Koken Co Ltd 眼科用コラーゲンゲル成形物
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
AU3066699A (en) 1998-03-03 1999-09-20 Johns Hopkins University, The Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
US6214790B1 (en) 1998-04-10 2001-04-10 Mayo Foundation For Medical Education And Research Neo-tryptophan
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US7084106B1 (en) 1999-01-19 2006-08-01 University Of Louisville Research Foundation, Inc. Application of a viral complement inhibitory protein in the treatment and diagnosis of Alzheimer's Disease
CA2361569A1 (en) 1999-02-12 2000-08-17 Dale P. Devore Injectable collagen-based system for delivery of cells or therapeutic agents
US20020102581A1 (en) 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
US7108982B1 (en) 1999-02-19 2006-09-19 University Of Iowa Research Foundation Diagnostics and the therapeutics for macular degeneration
ATE303816T1 (de) 1999-05-25 2005-09-15 King Faisal Specialist Hospita Neue therapeutische verwendung eines eine virale ansteckung modulierendes protein zur verhinderung von abstossung von fremdtransplantaten
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
GB9930659D0 (en) 1999-12-24 2000-02-16 Bio Discovery Ltd Inhibitors of complement activation
US20050020525A1 (en) 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20050032733A1 (en) 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US7011952B2 (en) 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
AU2001249622B2 (en) 2000-03-30 2007-06-07 Massachusetts Institute Of Technology RNA sequence-specific mediators of RNA interference
DK2026073T3 (en) 2000-04-29 2016-07-25 Univ Iowa Res Found Diagnosis and treatment of macular degeneration-related disorders
US6692759B1 (en) 2000-06-28 2004-02-17 The Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
WO2002011793A1 (fr) 2000-08-08 2002-02-14 Medical Information Services, Inc. Seringue pour preparation de necessaire d'injection, valve coulissante intermediaire pour seringues et preparation de necessaire d'injection
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
ES2333775T3 (es) 2000-10-10 2010-03-01 Genentech, Inc. Inhibicion de la activacion del complemento c5 para el tratamiento y la prevencion de rechazo de xenoinjerto retrasado o rechazo vascular agudo.
RU2322500C2 (ru) 2000-12-01 2008-04-20 Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. Малые молекулы рнк, опосредующие интерференцию рнк
CA2432438C (en) 2001-01-09 2011-04-26 Microchips, Inc. Flexible microchip devices for ophthalmic and other applications
US20050054596A1 (en) 2001-11-30 2005-03-10 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
PL371929A1 (en) 2001-11-09 2005-07-11 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases
WO2003047633A2 (en) 2001-12-04 2003-06-12 Nanospectra Biosciences, Inc. Treatment of angiogenesis disorders using targeted nanoparticles
ATE371680T1 (de) * 2002-01-16 2007-09-15 Biocompatibles Uk Ltd Polymerkonjugate
US7261876B2 (en) * 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
AUPS160602A0 (en) 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
WO2003105780A2 (en) 2002-06-18 2003-12-24 Epigenesis Pharmaceuticals, Inc. A dry powder oligonucleotide formulation, preparation and its uses
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
JP3976635B2 (ja) 2002-08-05 2007-09-19 久光製薬株式会社 キット製剤用注射器、注射器型キット製剤用中間摺動弁、及び、注射器型キット製剤、並びにｘ線造影剤キット製剤
EP2311480B1 (en) 2002-09-20 2013-06-26 The Trustees of The University of Pennsylvania Compstatin analogs with improved activity
WO2004028635A1 (en) 2002-09-27 2004-04-08 Novartis Ag Ocular gene therapy
CA2503490C (en) 2002-10-21 2012-04-03 Allvivo, Inc. Medical device surface coating comprising bioactive compound
WO2004041160A2 (en) 2002-10-30 2004-05-21 University Of Kentucky Research Foundation Methods and animal model for analyzing age-related macular degeneration
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20070065433A1 (en) 2003-02-21 2007-03-22 Mollnes Tom E Methods and compositions for the treatment of meconium aspiration syndrome
CA2515453C (en) 2003-02-21 2013-09-24 Tanox, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
US20050255144A1 (en) 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US20070116672A1 (en) 2003-09-05 2007-05-24 Kotwal Girish J Treatment of rheumatic diseases
WO2005023866A2 (en) 2003-09-10 2005-03-17 Baxter International Inc. Peptides that inhibit complement activation
ES2432112T3 (es) 2004-02-10 2013-11-29 The Regents Of The University Of Colorado, A Body Corporate Inhibición del factor B, de la vía alternativa del complemento y métodos relacionados
EP3736335A1 (en) 2004-02-12 2020-11-11 Archemix LLC Aptamer therapeutics useful in the treatment of complement-related disorders
US20050244472A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
MXPA06013029A (es) 2004-05-10 2007-02-12 Novacea Inc Prevencion de la restenosis arterial con compuestos de vitamina d activos.
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2006080951A2 (en) 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
US8043609B2 (en) 2004-10-08 2011-10-25 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders
US7947267B2 (en) 2004-10-08 2011-05-24 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders
JP2008520242A (ja) 2004-11-18 2008-06-19 イェール ユニバーシティ 視覚障害を処置するための方法および組成物
KR20130100207A (ko) 2005-02-14 2013-09-09 유니버시티 오브 아이오와 리써치 파운데이션 연령­관련 황반 변성의 치료 및 진단용 방법 및 시약
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
AU2006223108A1 (en) 2005-03-11 2006-09-21 Potentia Pharmaceuticals, Inc. Compositions comprising modulators of G-protein-coupled receptor for treatment of macular degeneration
DK1951279T3 (en) 2005-10-08 2017-07-31 Apellis Pharmaceuticals Inc COMPSTATIN AND ANALOGUES THEREOF FOR EYE DISEASES
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2007047626A1 (en) 2005-10-14 2007-04-26 Alcon, Inc. Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis
JP2009514888A (ja) 2005-11-04 2009-04-09 ジェネンテック・インコーポレーテッド 眼疾患を処置するための補体経路の阻害剤の使用
RS52429B (en) 2005-11-28 2013-02-28 The Trustees Of The University Of Pennsylvania POTENTIAL ANALYSIS OF COMPSTATIN
US20070149616A1 (en) 2005-12-22 2007-06-28 Alcon Manufacturing, Ltd. C3-Convertase Inhibitors for the Prevention and Treatment of Age-Related Macular Degeneration in Patients With At Risk Variants Of Complement Factor H
US20070196367A1 (en) 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
US8410045B2 (en) 2006-03-30 2013-04-02 Drais Pharmaceuticals, Inc. Camptothecin-peptide conjugates and pharmaceutical compositions containing the same
US8580735B2 (en) 2007-02-05 2013-11-12 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
CN106046370A (zh) 2007-02-28 2016-10-26 塞瑞纳治疗公司 聚噁唑啉poz化合物、合成其的方法、以及靶分子‑poz偶联物
EP2167103B1 (en) * 2007-07-19 2017-03-01 Allexcel, Inc. Self-assembling amphiphilic polymers as anticancer agents
US20110092446A1 (en) 2007-07-20 2011-04-21 Cedric Francois Compositions and methods for treatment of trauma
WO2009043027A2 (en) 2007-09-27 2009-04-02 Serina Therapeutics, Inc. Multi-armed forms of activated polyoxazoline and methods of synthesis thereof
CA2701470A1 (en) 2007-10-02 2009-04-09 Potentia Pharmaceuticals, Inc. Sustained delivery of compstatin analogs from gels
EP3042922B1 (en) 2008-01-11 2017-07-19 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
EP2257250A2 (en) 2008-01-29 2010-12-08 Gilbert H. Kliman Drug delivery devices, kits and methods therefor
WO2009121065A2 (en) 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
CN102149749B (zh) 2008-07-10 2014-06-25 塞瑞纳治疗公司 具有惰性端基的聚噁唑啉、由被保护的引发基团制备的聚噁唑啉以及相关化合物
PL2424557T3 (pl) 2009-05-01 2018-04-30 The Trustees Of The University Of Pennsylvania Zmodyfikowana kompstatyna z modyfikacjami szkieletu peptydowego i c-końca
US9291622B2 (en) 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
WO2011056799A1 (en) * 2009-11-05 2011-05-12 Sangart, Inc. Methods for preparing polyethylene glycol maleimide using n-(2-hydroxyethyl) maleimide as a starting material
EP2338520A1 (de) * 2009-12-21 2011-06-29 Ludwig Maximilians Universität Konjugat mit Zielfindungsligand und dessen Verwendung
US8625635B2 (en) 2010-04-26 2014-01-07 Cleversafe, Inc. Dispersed storage network frame protocol header
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
US20130324482A1 (en) 2010-07-09 2013-12-05 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
CA2813049A1 (en) * 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
BR112013028816B1 (pt) 2011-05-11 2020-12-15 Apellis Pharmaceuticals, Inc Análogos de compstatina, composição que os compreende e uso dos mesmos
AU2012272706B2 (en) 2011-06-22 2017-07-06 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
WO2013036778A2 (en) 2011-09-07 2013-03-14 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved pharmacokinetic properties
WO2014028861A1 (en) 2012-08-17 2014-02-20 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
HUE055564T2 (hu) 2012-11-15 2021-11-29 Apellis Pharmaceuticals Inc Hosszan ható compstatin-analógok és kapcsolódó készítmények, valamint módszerek
WO2014078734A2 (en) 2012-11-15 2014-05-22 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
US9512180B2 (en) 2012-12-19 2016-12-06 The Regents Of The University Of California Compstatin analogs
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
EP3023126B1 (en) 2013-07-16 2021-01-27 Beijing Mechanical Equipment Institute Fire engine suitable for fire-fighting in high-rise and super high-rise buildings
US9806963B2 (en) 2013-10-18 2017-10-31 Cellco Partnership Feature activation on device
JP6968787B2 (ja) * 2015-10-07 2021-11-17 アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals, Inc. 投与レジメン
WO2018187813A1 (en) * 2017-04-07 2018-10-11 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods

Also Published As

Publication number Publication date
CN105051057B (zh) 2019-11-19
BR112015011244A2 (pt) 2017-08-22
MX2015006154A (es) 2015-12-01
AU2020260435B2 (en) 2022-11-17
MX366404B (es) 2019-07-08
DK2920201T3 (da) 2020-04-14
JP2016505527A (ja) 2016-02-25
RU2015119165A (ru) 2017-01-10
US20210032289A1 (en) 2021-02-04
WO2014078731A2 (en) 2014-05-22
DK3660033T3 (da) 2021-07-05
HUE055564T2 (hu) 2021-11-29
NO2022017I1 (no) 2022-05-25
JP2021107441A (ja) 2021-07-29
CA2891673A1 (en) 2014-05-22
PL2920201T3 (pl) 2020-10-05
HUS2200026I1 (hu) 2022-06-28
US20160215020A1 (en) 2016-07-28
BR112015011244A8 (pt) 2018-01-23
HK1217336A1 (zh) 2017-01-06
SI3660033T1 (sl) 2021-09-30
JP7441271B2 (ja) 2024-02-29
AU2013344462A1 (en) 2015-06-04
JP2024056923A (ja) 2024-04-23
LT3660033T (lt) 2021-07-12
EP3660033A1 (en) 2020-06-03
US10035822B2 (en) 2018-07-31
EP3660033B1 (en) 2021-06-09
AU2023200929A1 (en) 2023-03-23
DK3660033T5 (da) 2022-06-27
JP2022120193A (ja) 2022-08-17
IL266004A (en) 2019-06-30
PT2920201T (pt) 2020-04-03
AU2018247243A1 (en) 2018-11-01
MX2019007709A (es) 2019-09-06
AU2020260435A1 (en) 2020-11-26
FR22C1025I1 (fr) 2022-07-22
CN105051057A (zh) 2015-11-11
EP2920201A4 (en) 2016-10-12
AU2018247243B2 (en) 2020-08-06
EP3660033B9 (en) 2022-06-22
HK1215445A1 (zh) 2016-08-26
LTPA2022010I1 (pt) 2022-06-27
JP6873167B2 (ja) 2021-05-19
US20230091471A1 (en) 2023-03-23
ES2780674T3 (es) 2020-08-26
JP7093871B2 (ja) 2022-06-30
CY1124474T1 (el) 2022-07-22
US11292815B2 (en) 2022-04-05
JP2019070011A (ja) 2019-05-09
EP2920201A2 (en) 2015-09-23
RU2705215C2 (ru) 2019-11-06
EP2920201B1 (en) 2020-01-08
IL238852A0 (en) 2015-06-30
US20190194254A1 (en) 2019-06-27
US10875893B2 (en) 2020-12-29
BR112015011244B1 (pt) 2022-08-09
AU2013344462B2 (en) 2018-07-12
RS62243B9 (sr) 2022-11-30
HRP20211342T1 (hr) 2021-11-26
WO2014078731A3 (en) 2014-07-31
FR22C1025I2 (fr) 2023-11-24
HRP20211342T2 (hr) 2022-08-19
EP3929206A1 (en) 2021-12-29
RS62243B1 (sr) 2021-09-30
NL301178I2 (nl) 2024-04-25
PL3660033T3 (pl) 2021-12-06
CN110882376B (zh) 2023-10-20
CN110882376A (zh) 2020-03-17
ES2879430T3 (es) 2021-11-22

Similar Documents

Publication Publication Date Title
HUS2200026I1 (hu) Hosszan ható compstatin-analógok és kapcsolódó készítmények, valamint módszerek
CY2022015I2 (el) Αναλογα κομπστατινης μακρας δρασης και σχετικες συνθεσεις και μεθοδοι
EP2836212A4 (en) NOVEL COMPOSITIONS AND METHOD
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
ZA201405746B (en) Rafamycin analogs and methods for making same
GB201220354D0 (en) Dermal compositions
EP2804611A4 (en) COMPOSITIONS FROM CHITOSAN
GB201223365D0 (en) Compositions
GB201315350D0 (en) Methods and compositions
GB201315347D0 (en) Methods and compositions
GB201210800D0 (en) Compositions
GB201209244D0 (en) Compositions
GB201201287D0 (en) Compositions
GB201220068D0 (en) Compositions
GB201219962D0 (en) Compositions
GB201219980D0 (en) Compositions
GB201219973D0 (en) Compositions
EP2926813A4 (en) METFORMIN-Orlistat COMPOSITIONS
GB201223148D0 (en) Compositions
GB201222702D0 (en) Compositions
GB201218959D0 (en) Compositions
GB201209189D0 (en) Compositions
GB201209187D0 (en) Compositions
GB201204102D0 (en) Compositions
GB201204103D0 (en) Compositions